White Papers

Click a tab heading (all caps) and a new folder opens.


Early Release

A Holistic Approach to Corrections Early Release COVID-19 Strategies

ARC and RHOAR

A White Paper highlighting ARC and the Fletcher Group’s RHOAR Initiative

Qualified Allocation Plans

How To Navigate Qualified Allocation Plans in Recovery Housing Development


Long-Term RH Benefits

Role of Recovery Residences in Long-term Addiction Recovery

NARR FAQs

Frequently Asked Questions from the National Association of Recovery Residences


Early Help

How Recovery Homes Help People In Early Recovery

Key Role

The Key Role of Prevention In Addressing Substance Use In America

Best Practices

Best Practices and Suggested Guidelines for OUD Treatment

Opioid Update

An Update On The Opioid Crisis


Oxford House

The Characteristics and Effectiveness Of Oxford House Recovery Homes

Criminal Justice Principles

Principles of Drug Abuse Treatment for Criminal Justice Populations: A Research-Based Guide

Social Model Principles

Maximizing Social Model Principles in Residential Recovery Settings

Sober Living Outcomes

Sober Living Houses for Alcohol and Drug Dependence Outcomes





RH for Policymakers

Recovery Housing Issue Brief For State Policymakers

RH In Ohio

Recovery Housing in Ohio Findings and Recommendations


Research Benefits

Challenges and Rewards of Conducting Research on Recovery Residences for Alcohol and Drug Disorders


RH Benefits

Recovery Housing: Assessing the Evidence

RH In Massachusetts

Study Of Sober Housing In Massachusetts

Philadelphia Study

Recovery Resource Mapping: Results of a Philadelphia Recovery Home Survey

Support Institutions

Mobilizing Support Beyond Professional Addiction Treatment and Recovery

MAT Availability

Study Shows Low Availability Of Medications for Opioid Use Disorders (MOUDs) in Residential Treatment Settings



This web page is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $10.4 million. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the U.S. Government.